f A spiral CT of the thorax and abdomen will be performed. If a subject cannot have a CT scan (e.g. allergy to contrast dye) an MRI should be performed. CT scans may be done within 1 week prior to or after scheduled visit. Optional FDG -PET may be done. A clinical assessment of tumor status using modified RECIST will be completed. g Complete physical examinations will be conducted at baseline and EOS; symptom -directed physical examinations to be conducted on Day 1 of dosing weeks. h Blood pressure, pulse, respiratory rate, temperature and pulse oximetry are required as indicated. Weight will be taken on Day 1 of dosing weeks. Height required at screening only. Pre-dose blood pressure should be performed in a supine position after the subject has been resting for at least 5 minutes i Pregnancy tests will be administered to women of childbearing potential: serum pregnancy test is required at screening, and pregnancy tests (urine or serum) are required before doses on Day 1 of CRS -207- dosing weeks. Pregnancy tests (urine or serum) only re quired at follow -up visits at which maintenance vaccinations will be administered. j Creatinine clearance calculated by Cockcroft -Gault formula = {[(140 -age) x weight in kilograms] x [0.85 if female] }/[72 x creatinine in mg/dL] k Clinical hematology: CBC with differential ANC, platelet count; serum chemistry: sodium, potassium, chloride, bicarbonate, glucose, BUN, creatinine, L DH, ALT, AST, alkaline phosphatase, bilirubin (total, direct, and indirect), total protein, albumin, calcium, magnesium, uric acid and phosphate. Blood draws may be taken up to 3 days prior to dosing with CRS -207. l Clinical hematology and chemistry tests to be taken prior to each chemotherapy treatment. m Tumor markers to be assessed include Mesothelin, CA -125, and plasma osteopontin; other markers may also be assessed . n Adverse Events (AEs) and concomitant medications review. A phone call follow -up for AEs and concomitant medications will be conducted on day 2 ± 1 day s after each CRS- 207 infusion. o Up to 200 mL of whole blood to be processed within 6 hours into peripheral blood mononuclear cells (PBMCs) and stored frozen in liquid nitrogen. p Whole blood (10 mL ) will be collected between 20 and 26 hours after start of dosing for assessment of Lm and mesothelin immunity. q The HLA -typing should include type A and B of class I antigens , low resolution. r Attempts to obtain surgical or biopsy archival tumor samples will be made for every subject until the sample is obtained or documentation that the sample cannot be obtained.